Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NR63
UPID:
CP26B_HUMAN
Alternative names:
Cytochrome P450 26A2; Cytochrome P450 retinoic acid-inactivating 2; Retinoic acid-metabolizing cytochrome
Alternative UPACC:
Q9NR63; B2R8M7; B7Z2K6; B7Z2P4; B7Z3B8; E4W5W7; Q32MC0; Q53TW1; Q9NP41
Background:
Cytochrome P450 26B1, also known as Cytochrome P450 retinoic acid-inactivating 2, plays a pivotal role in the metabolism of retinoic acids, vital signaling molecules derived from vitamin A. It primarily hydroxylates all-trans-retinoic acid, regulating its homeostasis and signaling. This enzyme is crucial in germ cell development, skeletal patterning, ossification of bone, and the establishment of synovial joints.
Therapeutic significance:
Understanding the role of Cytochrome P450 26B1 could open doors to potential therapeutic strategies. Its involvement in Radiohumeral fusions with other skeletal and craniofacial anomalies highlights its significance in skeletal development and potential targets for intervention.